TY - JOUR T1 - Practical aspects of targeting IL-6 in COVID-19 disease JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med DO - 10.3949/ccjm.87a.ccc018 AU - Cassandra Calabrese AU - Prabalini Rajendram AU - Gretchen L. Sacha AU - Leonard Calabrese Y1 - 2020/05/14 UR - http://www.ccjm.org/content/early/2020/10/07/ccjm.87a.ccc018.abstract N2 - Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of immune-mediated disease states, they have not been used often in the intensive care setting, and new data question their efficacy. This brief review provides practical information on their administration and safety. ER -